Guide

As of July 2026, two FDA-approved oral GLP-1 weight loss pills exist: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only, not weight loss. Medicare covers both pills at $50/mo via the GLP-1 Bridge Demonstration (live July 1, 2026).

Updated July 2026: Medicare Part D now covers Foundayo, Wegovy, and Zepbound for weight loss (live since July 1, 2026) via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions, take any time.

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified April 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Verified April 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified April 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Verified April 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup options.